Tissue Regenix Group PLC dCELL® technology presented at Royal Society event
September 10 2014 - 4:00AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
10 September 2014
Tissue Regenix Group Plc
Tissue Regenix's dCELL(R) heart valve technology to be presented
at prestigious Royal Society event
YORK, 10(th) September 2014 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Group"), the regenerative medical devices
company, announces that its long-term clinical collaborator,
Professor Francisco da Costa, has been asked to present the
findings from his study into the Group's dCELL(R) heart valve at
the 6th Biennial Heart Valve and Tissue Engineering Meeting at the
Royal Society in London, on 12(th) September 2014.
The study findings suggest that fresh decellularised human heart
valves, developed using Tissue Regenix's patented dCELL(R)
technology, could provide a more effective treatment than
cryopreserved decellularised pulmonary valve substitutes.
Professor Francisco da Costa is an internationally renowned
cardiac surgeon from Pontifical University of Parana, Brazil, and
the data in the report has been accumulated from more than 160
patient implants undertaken during Ross Procedures at his
institution between 2005 and 2013 with follow-up review and patient
monitoring up to the present date.
Key findings of the study include that the fresh dCELL(R) heart
valve has shown:
-- No reoperation up to now in a relatively young patient population (mean age 30 years)
-- No peak gradient above 40mmHg for up to six years
-- Significantly higher freedom from valve dysfunction (97% vs 85%)
-- No calcification
-- Partial re-population of the grafts
-- Particularly good results in younger patients
-- First indication that commonly used standard cryopreservation is unnecessary
Tissue Regenix's dCELL(R) technology decellularises human donor
heart valves, producing an inert scaffold which is implanted into
the patient to act as a mechanical scaffold that is populated by
the patient's own cells. The dCELL(R) heart valve regenerates to
become part of the patient's body, providing a more durable repair
with proven significantly reduced risk of rejection and
infection.
Antony Odell, CEO of Tissue Regenix commented: "We are excited
to see continued recognition for the effectiveness of the dCELL(R)
heart valve technology, especially at this prestigious Royal
Society Biennial Heart Valve and Tissue Engineering Meeting in
London.
"Professor da Costa has collaborated with Tissue Regenix for
more than eight years to develop new, regenerative medicine
treatments for patients with heart disease, and the data based on
his studies show strong results and great promise for the dCELL(R)
heart valve technology, targeted at the global tissue heart valve
market which is worth in excess of $1.0bn a year.
"This latest announcement comes on the back of further, recent
positive updates on the development and commercialisation of our
dCELL(R) treatments. This includes the DermaPure(TM) decellularised
dermal allograft, where the US commercialisation continues at pace
with initial orders having been received, and shipped to customers
and continued progress being made in securing approvals by hospital
new product evaluation committees - a key element in the inpatient
sales process.
- ENDS -
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Andrew Adie
Stephanie Dobbs
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLMRTMBBMBPI
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024